
Genesis Research Group (Genesis) launches Keystone, its modular platform for Integrated Evidence Generation Planning (IEGP), at ISPOR Europe 2026.
Initial focus on named-patient access in selected European and MENA markets, providing a capital-efficient foundation for broader commercialization

In the third issue of The Vector, Genesis Research asked 15 payers across France, Germany, Italy, Spain, and the UK how they believe the new EU General Pharmaceutical Legislation will...

The publication of the GLOBE Final Rule provides important clarity on the administration's approach to MFN pricing and what it could mean for pharmaceutical pricing, reimbursement, and access strategy globally....

Genesis Research Group today announced the appointment of Sarah Alwardt, PhD, as Executive Vice President, RWE/HEOR. She joins the Executive Leadership Team and will lead the company’s global real-world evidence...

True "beyond-the-pill" strategy requires shifting from a prescriptive model to a supportive one—using personalized digital tools and authentic patient voices to drive adherence, improve outcomes, and prove value.

The report forecasts a rise in cases in the US, the UK, Canada, Australia and Europe

Genesis Research Group today announced that its EVID AI evidence synthesis platform will be available free of charge through 2026 for approved life sciences organizations and eligible researchers. “Run it...

The company has also opened its first dedicated genetic medicine facility in Indiana in the US

With a 10-day ceasefire between Israel and Lebanon in effect, oil prices are retreating from recent highs

With GENEROUS, GUARD, and GLOBE all released since December, 185 pages of policy will materially impact U.S. drug pricing — and yes, it's a lot to digest. In a new...